Features of Invasive Aspergillosis Caused by Aspergillus flavus, France, 2012-2018.

Fiche publication

Date publication

mai 2025

Journal

Emerging infectious diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HERBRECHT Raoul

Tous les auteurs :
Bertin-Biasutto L, Paccoud O, Garcia-Hermoso D, Denis B, Boukris-Sitbon K, Lortholary O, Bretagne S, Gits-Muselli M, Herbrecht R, Letscher-Bru V, Danion F, Cassaing S, Morio F, Nourrisson C, Pihet M, Sasso M, Desoubeaux G, Durieux MF, Bonhomme J, Chachaty E, Chouaki T, Desbois-Nogard N, Alanio A, Gangneux JP, Lanternier F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40305205

Résumé

Invasive aspergillosis (IA) caused by Aspergillus flavus remains poorly described. We retrospectively analyzed 54 cases of IA caused by A. flavus reported in France during 2012-2018. Among cases, underlying IA risk factors were malignancy, solid organ transplantation, and diabetes. Most (87%, 47/54) infections were localized, of which 33 were pleuropulmonary and 13 were ear-nose-throat (ENT) infection sites. Malignancy (70% [23/33]) and solid organ transplantation (21% [7/33]) were the main risk factors in localized pulmonary infections, and diabetes mellitus was associated with localized ENT involvement (61.5%, [8/13]). Fungal co-infections were frequent in pulmonary (36%, 12/33) but not ENT IA (0 cases). Antifungal monotherapy was prescribed in 45/50 (90%) cases, mainly voriconazole (67%, 30/45). All-cause 30-day case-fatality rates were 39.2% and 90-day rates were 47.1%, and rates varied according to risk factor, IA site, and fungal co-infections. Clinicians should remain vigilant for A. flavus and consider it in the differential diagnosis for IA.